Expression of EGF receptor (EGFR) is frequently elevated in squamous cell carcinoma of the
head and neck (SCCHN). Cetuximab is an anti-EGFR monoclonal antibody that has been …

Activating mutations in the EGF receptor (EGFR) are associated with clinical responsiveness
to EGFR tyrosine kinase inhibitors (TKI), such as erlotinib and gefitinib. However, resistance …

Background To assess management patterns and outcome in patients with glioblastoma
multiforme (GBM) treated during 2008–2010 in Spain. Methods Retrospective analysis of …

To search for sequence variants conferring risk of nonmedullary thyroid cancer, we focused
our analysis on 22 SNPs with a P < 5 × 10 −8 in a genome-wide association study on levels …

The great majority of thyroid cancers are of the non-medullary type. Here we report findings
from a genome-wide association study of non-medullary thyroid cancer, including in total …

Objectives The aim of this study was to confirm the efficacy of the ERBITAX scheme (paclitaxel
80 mg/m 2 weekly and cetuximab 400 mg/m 2 loading dose, and then 250 mg/m 2 weekly…

Multiple-drug resistance in human cancer is a major problem. To circumvent this issue,
clinicians combine several drugs. However, this strategy could backfire resulting in more toxic or …

Gold glyconanoparticles loaded with the listeriolysin O peptide 91–99 (GNP-LLO 91-99 ), a
bacterial peptide with anti-metastatic properties, are vaccine delivery platforms facilitating …

High-grade gliomas (HGG) are the most common primary brain malignancies and account
for more than half of all malignant primary brain tumors. The new 2021 WHO classification …

Dendritic cell (DC) vaccines are cancer vaccines used currently as melanoma therapies.
They act as adjuvants initiating the immune responses, but not only as they can also have …